Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas

NCT02333565 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Meningiomas
Resistant Meningiomas

Interventions

DRUG: Everolimus
DRUG: Octreotide

Sponsor

Assistance Publique Hopitaux De Marseille